Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 12/20 | 0.73 |
| ▸ | NPC1 | O15118 | 11/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.73 |
| ▸ | TP53 | P04637 | 5/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.73 |
| ▸ | TSHR | P16473 | 2/20 | 0.73 |
| ▸ | POLB | P06746 | 3/20 | 0.71 |
| ▸ | MAPT | P10636 | 3/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | THRB | P10828 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 7/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.66 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.60 |
| ▸ | ACP1 | P24666 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23529364 | 0.84 | MAPT (0.73) | RAB9ANPC1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL23529399 | 0.84 | RAB9A (0.72) | RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL23529400 | 0.84 | RAB9A (0.72) | RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL23529366 | 0.84 | RAB9A (0.72) | RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL4918200 | 0.83 | RAB9A (0.71) | RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL23529343 | 0.81 | RAB9A (0.68) | RAB9ANPC1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL23529381 | 0.81 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL6229059 | 0.79 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL23529391 | 0.79 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL23529350 | 0.78 | RAB9A (0.64) | RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622896-B2 | Antiviral compounds, compositions and methods of use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2026-05-12 | — | — | US | disclosed |
| US-20230105935-A1 | ANTIVIRAL COMPOUNDS, COMPOSITIONS AND METHODS OF USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2023-04-06 | — | — | US | disclosed |
| EP-4077320-A1 | ANTIVIRAL COMPOUNDS, COMPOSITIONS AND METHODS OF USE | The University of British Columbia (CA) | 2022-10-26 | — | — | EP | disclosed |
| CN-115151536-A | Antiviral compounds, compositions and methods of use | 不列颠哥伦比亚大学 | 2022-10-04 | — | — | CN | disclosed |
| WO-2021119808-A1 | ANTIVIRAL COMPOUNDS, COMPOSITIONS AND METHODS OF USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021119808-A1 | ANTIVIRAL COMPOUNDS, COMPOSITIONS AND METHODS OF USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230105935-A1 | ANTIVIRAL COMPOUNDS, COMPOSITIONS AND METHODS OF USE | SARS1, RNMT, EIF2AK2 | RAB9A 3618/4885NPC1 137/4885SMN1; SMN2 2570/4885 |
| US-12622896-B2 | Antiviral compounds, compositions and methods of use | SARS1, NSUN2, ZC3HAV1 | RAB9A 3269/4885NPC1 30/4885SMN1; SMN2 1838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.